Sri Srinivasa Drugs Profile
Key Indicators
- Authorised Capital ₹ 6.00 M
as on 08-07-2024
- Paid Up Capital ₹ 4.08 M
as on 08-07-2024
- Company Age 34 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 8.06 M
as on 08-07-2024
- Revenue %
(FY 2023)
- Profit -382.61%
(FY 2023)
- Ebitda -382.61%
(FY 2023)
- Net Worth -4.93%
(FY 2023)
- Total Assets 34.05%
(FY 2023)
About Sri Srinivasa Drugs
The Corporate was formerly known as Sri Srinivasa Drugs Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 6.00 M and a paid-up capital of Rs 4.08 M.
The company has closed loans amounting to ₹8.06 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Jagannathan Balaji and Pandurengan Venkatesan serve as directors at the Company.
- CIN/LLPIN
U24231TN1989PTC018522
- Company No.
018522
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Dec 1989
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Sri Srinivasa Drugs?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jagannathan Balaji  | Director | 07-Mar-2007 | Current |
| Pandurengan Venkatesan | Director | 07-Dec-2012 | Current |
Financial Performance of Sri Srinivasa Drugs.
Sri Srinivasa Drugs Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 382.61% decrease in profit. The company's net worth dipped by a decrease of 4.93%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sri Srinivasa Drugs?
In 2023, Sri Srinivasa Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Venkatnarayana Metals & Realtors Private LimitedActive 33 years 11 monthsJagannathan Balaji and Pandurengan Venkatesan are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
The Tamil Nadu Industrial Investment Corpn. Ltd. Creation Date: 10 Mar 1995 | ₹0.06 M | Satisfied |
The South Indian Bank Limited Creation Date: 05 Aug 1994 | ₹5.00 M | Satisfied |
The Tamil Nadu Industrial Investment Corpn. Limited Creation Date: 18 Feb 1994 | ₹0.24 M | Satisfied |
How Many Employees Work at Sri Srinivasa Drugs?
Unlock and access historical data on people associated with Sri Srinivasa Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sri Srinivasa Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sri Srinivasa Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
